AstraZeneca's top products based on revenue 2021-2022
AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. As of 2022, AstraZeneca’s top pharmaceutical product by revenue was Tagrisso, a medication used in the treatment of non-small-cell lung carcinomas. During that year, Tagrisso generated 5.44 billion U.S. dollars in revenue for the company. The second-highest revenue generator for AstraZeneca in 2021 was Vaxzevria, the COVID-19 vaccine, generating about 3.9 billion U.S. dollars, but dropping down to 1.8 billion dollars in 2022.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2022, the highest proportion of AstraZeneca’s employees was based in Europe. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2022, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2022, almost 23 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2022, AstraZeneca was projected to be among the world’s top six pharmaceutical companies according to the number of drugs they had under development at that time.
AstraZeneca company profile
AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2022, the highest proportion of AstraZeneca’s employees was based in Europe. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2022, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.
AstraZeneca’s R&D
AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2022, almost 23 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2022, AstraZeneca was projected to be among the world’s top six pharmaceutical companies according to the number of drugs they had under development at that time.
